Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPaQ
- Development stage
- Phase 3
- Lead developer
- Otsuka Pharmaceutical Development & Commercialization
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BPaQ is an investigational combination anti-tuberculosis regimen consisting of bedaquiline, pretomanid, and quabodepistat (OPC-167832). Developed by Otsuka Pharmaceutical, the regimen is designed to treat rifampicin-resistant (RR-TB) and multidrug-resistant tuberculosis (MDR-TB). Quabodepistat is a novel carbostyril derivative that acts as a potent inhibitor of decaprenylphosphoryl-β-D-ribose-2'-oxidase (DprE1), an essential enzyme for Mycobacterium tuberculosis to synthesize the cell wall component arabinogalactan. Bedaquiline inhibits mycobacterial ATP synthase, disrupting energy production, while pretomanid is a nitroimidazole that inhibits mycolic acid synthesis and causes respiratory poisoning in the bacteria. The regimen is currently being evaluated in the Phase 3 QUANTUM-TB trial to determine if it can shorten treatment duration to 4 or 6 months compared to the current standard of care.
- Other names
- Bedaquiline + Pretomanid + Quabodepistat
02
Targets
AtpE (Mycobacterium tuberculosis ATP synthase subunit c)DendrinNeuraminidaseDprE1 (Decaprenylphosphoryl-beta-D-ribose oxidase)MmpL3 (Mycobacterial membrane protein Large 3)
Beyond the preview
Go deeper on BPaQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPaQ.